Association of Human Immunodeficiency Virus Infection with Exposure to Highly Active Antiretroviral Therapy and Its Adverse Cardiovascular Effects

Steven E Lipshultz, Tracie L Miller, James D. Wilkinson, Gwendolyn B Scott, Gabriel Somarriba, Thomas R. Cochran, Catherine M. Mas, Stacy D. Fisher

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Human immunodeficiency virus (HIV) infection is a cause of acquired heart disease, particularly of accelerated atherosclerosis, symptomatic heart failure, and pulmonary arterial hypertension. Cardiac complications in persons living with HIV are becoming more relevant as longevity improves. Before the advent of highly active antiretroviral therapy (HAART), the 2- to 5-year incidence of symptomatic heart failure ranged from 4 to 28% in HIV patients. Patients both before and after HAART availability also often have asymptomatic abnormalities in cardiovascular structure. Echocardiographic changes indicate left ventricular (LV) systolic dysfunction, LV hypertrophy, and left atrial dilation in patients followed on HAART therapy. In non-HIV infected infants born to HIV-infected mothers, fetal exposure to antiretroviral therapy is associated with reduced LV dimension, LV mass, and septal wall thickness, and with higher LV fractional shortening and contractility during the first two years of life. Routine, systematic, and comprehensive cardiac evaluation, including a thorough history and directed laboratory assays, are essential for the care of HIV-infected adults and children because cardiovascular illness has become a part of long-term survival in patients with HIV infection. Asymptomatic cardiac disease related to HIV can be fatal, and secondary effects of HIV infection often disguise cardiac symptoms, so systematic echocardiographic monitoring is warranted.

Original languageEnglish (US)
Title of host publicationHeart and Toxins
PublisherElsevier Inc.
Pages363-405
Number of pages43
ISBN (Print)9780124165991, 9780124165953
DOIs
StatePublished - Sep 8 2014

Fingerprint

Highly Active Antiretroviral Therapy
Virus Diseases
HIV
Heart Diseases
Heart Failure
Cardiovascular Abnormalities
Asymptomatic Diseases
Left Ventricular Dysfunction
Left Ventricular Hypertrophy
Pulmonary Hypertension
Dilatation
Atherosclerosis
History
Mothers
Viruses
Survival
Incidence
Therapeutics

Keywords

  • AIDS
  • Antiretroviral therapies
  • Cardiac outcomes
  • Cardiovascular risk
  • Children
  • HIV
  • Therapeutic complications

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lipshultz, S. E., Miller, T. L., Wilkinson, J. D., Scott, G. B., Somarriba, G., Cochran, T. R., ... Fisher, S. D. (2014). Association of Human Immunodeficiency Virus Infection with Exposure to Highly Active Antiretroviral Therapy and Its Adverse Cardiovascular Effects. In Heart and Toxins (pp. 363-405). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-416595-3.00012-8

Association of Human Immunodeficiency Virus Infection with Exposure to Highly Active Antiretroviral Therapy and Its Adverse Cardiovascular Effects. / Lipshultz, Steven E; Miller, Tracie L; Wilkinson, James D.; Scott, Gwendolyn B; Somarriba, Gabriel; Cochran, Thomas R.; Mas, Catherine M.; Fisher, Stacy D.

Heart and Toxins. Elsevier Inc., 2014. p. 363-405.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lipshultz, SE, Miller, TL, Wilkinson, JD, Scott, GB, Somarriba, G, Cochran, TR, Mas, CM & Fisher, SD 2014, Association of Human Immunodeficiency Virus Infection with Exposure to Highly Active Antiretroviral Therapy and Its Adverse Cardiovascular Effects. in Heart and Toxins. Elsevier Inc., pp. 363-405. https://doi.org/10.1016/B978-0-12-416595-3.00012-8
Lipshultz, Steven E ; Miller, Tracie L ; Wilkinson, James D. ; Scott, Gwendolyn B ; Somarriba, Gabriel ; Cochran, Thomas R. ; Mas, Catherine M. ; Fisher, Stacy D. / Association of Human Immunodeficiency Virus Infection with Exposure to Highly Active Antiretroviral Therapy and Its Adverse Cardiovascular Effects. Heart and Toxins. Elsevier Inc., 2014. pp. 363-405
@inbook{c985d75b864b431bb41de1b566cd6d81,
title = "Association of Human Immunodeficiency Virus Infection with Exposure to Highly Active Antiretroviral Therapy and Its Adverse Cardiovascular Effects",
abstract = "Human immunodeficiency virus (HIV) infection is a cause of acquired heart disease, particularly of accelerated atherosclerosis, symptomatic heart failure, and pulmonary arterial hypertension. Cardiac complications in persons living with HIV are becoming more relevant as longevity improves. Before the advent of highly active antiretroviral therapy (HAART), the 2- to 5-year incidence of symptomatic heart failure ranged from 4 to 28{\%} in HIV patients. Patients both before and after HAART availability also often have asymptomatic abnormalities in cardiovascular structure. Echocardiographic changes indicate left ventricular (LV) systolic dysfunction, LV hypertrophy, and left atrial dilation in patients followed on HAART therapy. In non-HIV infected infants born to HIV-infected mothers, fetal exposure to antiretroviral therapy is associated with reduced LV dimension, LV mass, and septal wall thickness, and with higher LV fractional shortening and contractility during the first two years of life. Routine, systematic, and comprehensive cardiac evaluation, including a thorough history and directed laboratory assays, are essential for the care of HIV-infected adults and children because cardiovascular illness has become a part of long-term survival in patients with HIV infection. Asymptomatic cardiac disease related to HIV can be fatal, and secondary effects of HIV infection often disguise cardiac symptoms, so systematic echocardiographic monitoring is warranted.",
keywords = "AIDS, Antiretroviral therapies, Cardiac outcomes, Cardiovascular risk, Children, HIV, Therapeutic complications",
author = "Lipshultz, {Steven E} and Miller, {Tracie L} and Wilkinson, {James D.} and Scott, {Gwendolyn B} and Gabriel Somarriba and Cochran, {Thomas R.} and Mas, {Catherine M.} and Fisher, {Stacy D.}",
year = "2014",
month = "9",
day = "8",
doi = "10.1016/B978-0-12-416595-3.00012-8",
language = "English (US)",
isbn = "9780124165991",
pages = "363--405",
booktitle = "Heart and Toxins",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Association of Human Immunodeficiency Virus Infection with Exposure to Highly Active Antiretroviral Therapy and Its Adverse Cardiovascular Effects

AU - Lipshultz, Steven E

AU - Miller, Tracie L

AU - Wilkinson, James D.

AU - Scott, Gwendolyn B

AU - Somarriba, Gabriel

AU - Cochran, Thomas R.

AU - Mas, Catherine M.

AU - Fisher, Stacy D.

PY - 2014/9/8

Y1 - 2014/9/8

N2 - Human immunodeficiency virus (HIV) infection is a cause of acquired heart disease, particularly of accelerated atherosclerosis, symptomatic heart failure, and pulmonary arterial hypertension. Cardiac complications in persons living with HIV are becoming more relevant as longevity improves. Before the advent of highly active antiretroviral therapy (HAART), the 2- to 5-year incidence of symptomatic heart failure ranged from 4 to 28% in HIV patients. Patients both before and after HAART availability also often have asymptomatic abnormalities in cardiovascular structure. Echocardiographic changes indicate left ventricular (LV) systolic dysfunction, LV hypertrophy, and left atrial dilation in patients followed on HAART therapy. In non-HIV infected infants born to HIV-infected mothers, fetal exposure to antiretroviral therapy is associated with reduced LV dimension, LV mass, and septal wall thickness, and with higher LV fractional shortening and contractility during the first two years of life. Routine, systematic, and comprehensive cardiac evaluation, including a thorough history and directed laboratory assays, are essential for the care of HIV-infected adults and children because cardiovascular illness has become a part of long-term survival in patients with HIV infection. Asymptomatic cardiac disease related to HIV can be fatal, and secondary effects of HIV infection often disguise cardiac symptoms, so systematic echocardiographic monitoring is warranted.

AB - Human immunodeficiency virus (HIV) infection is a cause of acquired heart disease, particularly of accelerated atherosclerosis, symptomatic heart failure, and pulmonary arterial hypertension. Cardiac complications in persons living with HIV are becoming more relevant as longevity improves. Before the advent of highly active antiretroviral therapy (HAART), the 2- to 5-year incidence of symptomatic heart failure ranged from 4 to 28% in HIV patients. Patients both before and after HAART availability also often have asymptomatic abnormalities in cardiovascular structure. Echocardiographic changes indicate left ventricular (LV) systolic dysfunction, LV hypertrophy, and left atrial dilation in patients followed on HAART therapy. In non-HIV infected infants born to HIV-infected mothers, fetal exposure to antiretroviral therapy is associated with reduced LV dimension, LV mass, and septal wall thickness, and with higher LV fractional shortening and contractility during the first two years of life. Routine, systematic, and comprehensive cardiac evaluation, including a thorough history and directed laboratory assays, are essential for the care of HIV-infected adults and children because cardiovascular illness has become a part of long-term survival in patients with HIV infection. Asymptomatic cardiac disease related to HIV can be fatal, and secondary effects of HIV infection often disguise cardiac symptoms, so systematic echocardiographic monitoring is warranted.

KW - AIDS

KW - Antiretroviral therapies

KW - Cardiac outcomes

KW - Cardiovascular risk

KW - Children

KW - HIV

KW - Therapeutic complications

UR - http://www.scopus.com/inward/record.url?scp=84942693816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942693816&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-416595-3.00012-8

DO - 10.1016/B978-0-12-416595-3.00012-8

M3 - Chapter

AN - SCOPUS:84942693816

SN - 9780124165991

SN - 9780124165953

SP - 363

EP - 405

BT - Heart and Toxins

PB - Elsevier Inc.

ER -